R&Dplatform

联系我们

国际针灸合作委员会关于变更办公地址的通知

中国民间中医医药研究开发协会国际针灸合作委员会

办公地点现在已经搬迁至西城区西直门南小街国英园一号楼824室,

同时为方便大家联系,固定电话已经变更

新号码010—58562339。特此通知。

地址:北京西城区西直门南小街国英园一号楼824室

邮编:100035

电话:010-58562339

传真:010-58562339

邮箱:cngjzj@163.com

网站(点击网址直接链接↓):http://www.cngjzj.com/

博客(点击网址直接链接↓):http://blog.sina.com.cn/cngjzj

交通路线图 (点击观看大图)

到西城区西直门南小街国英园一号楼行驶路线

机场线路1

从首都机场乘坐机场专线,在东直门站下车换乘地铁2号线开往西直门方向,在西直门站 C 口出站:

1、沿西直门内大街向东直行100米,右拐到西直门南小街,向南步行到丁字路口即到国英园1号楼楼下。

2、向南直行50米,绕过 国二招宾馆 沿着中大安胡同向东到西直门南小街,向南步行到丁字路口即到国英园1号楼楼下。

机场线路2

从首都机场内乘坐机场直达西单的大巴,在西单站下车,乘坐出租车到西直门南小街国英园1号楼。

附近公交地铁:

公交官园站:107路,运通106路

公交西直门南:387路,44路,800内环,816路,820内环,845路

地铁车公庄:地铁二号线

地铁西直门:地铁二号线

公交车公庄东:107路,118路,701路

公交车公庄北:209路,375路,392路

您现在的位置是: 首页 >> R&Dplatform >> R&Dplatform

Group method to raise 1.46 billion to increase product research and development and production

2015年11月05日

复制链接 打印 大 中 小

<

Group method to raise 1.46 billion to increase product research and development and production

Source: HeXun author: gu

The 2015-11-03 09:26:25

Events: the company intends to non-public offering is not more than $1.46 billion for "oprah azole series of innovative products depth development and industrialization of upgrade", "therapeutic antibody drug research and development and industrialization projects", "long-lasting microsphere technology r&d platform construction project" and added liquidity and repay bank loans.

Shekinah analysis:

1, the company has been in the anti-tumor Chinese medicine auxiliary medication, assisted reproduction, digestive drugs, and other characteristics of specialized care field market advantage, at the same time continue to strengthen with monoclonal antibody drugs as the core of biological medicine field, and actively layout with gene diagnosis related business as the core of precision medical field.

2, ai oprah azole series of innovative products depth development and industrialization of upgrade in existing products "oprah azole enteric-coated metformin hydrochloride" lian (1) the depth development, on the basis of the product is used in the treatment of duodenal ulcer. 12-14 years, the company to the production of thiazole enteric-coated metformin hydrochloride is about 3 million, 5.2 million and 5.2 million respectively, fast growth; Project implementation will be ai oprah azole new applicable disease and new products and improve production capacity.

3, a therapeutic antibody drug research and development and industrialization projects will produce single resistance in the field of autoimmune diseases and cancer drugs, used in the treatment of rheumatoid arthritis and breast cancer. Is expected to average annual net profit of 340 million yuan, embedded yields (after tax) is 40.89%, good prospects.

4, long-acting microsphere technology r&d platform construction project will build long-term microspheres controlled-release formulation technology platform, the implementation of research and development of new varieties and pilot, production workshop construction.

5, the implementation of the project will help the company expand the scale of existing products, improve product market share; Is beneficial to the optimization of products structure, and further improve the level of product quality and process technology, comprehensive research and development ability and independent innovation ability of ascension.